Onconova Therapeutics (NASDAQ:ONTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Onconova Therapeutics (NASDAQ:ONTX) in a research report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Onconova Therapeutics Stock Performance

Onconova Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.45. The stock has a market capitalization of $20.90 million, a P/E ratio of -1.09 and a beta of 1.38. The company’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.74.

About Onconova Therapeutics

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.